Delcath Q2 2024 Earnings Report
Key Takeaways
Delcath Systems reported a significant increase in revenue for the second quarter of 2024, driven by sales of HEPZATO KITâ„¢ and CHEMOSAT. The company is focused on expanding the adoption of HEPZATO KIT and advancing its clinical programs.
Recognized second quarter revenue of $6.6 million from HEPZATO KIT and $1.2 million from CHEMOSAT sales.
Activated three HEPZATO KIT treating centers in the US during the second quarter, with an additional center in July, totaling eight active centers.
Received New Technology Add-on Payment status (NTAP) for HEPZATO from CMS effective August 1, 2024.
Submitted the final principal payment due to Avenue Venture Opportunities Fund, L.P. on August 1, 2024.
Delcath
Delcath
Forward Guidance
Delcath is optimistic about the continued adoption of HEPZATO KIT and its potential as a key therapeutic approach for metastatic uveal melanoma patients.